KYMR Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Zacks Investment Research

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

8 days ago - By: Benzinga

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts

24 days ago - By: Zacks Investment Research - Mentions: GILD SNY

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline

a month ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

a month ago - By: Benzinga

Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views

2 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

2 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

3 months ago - By: Zacks Investment Research - Mentions: CDXS

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: The Motley Fool - Mentions: GILD

Kymera Revenue Drops 55 Percent in Q2

3 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

3 months ago - By: Zacks Investment Research - Mentions: GSK GILD

GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up

3 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

4 months ago - By: Yahoo Finance - Mentions: MS PRMB

Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow

4 months ago - By: Yahoo Finance - Mentions: GILD

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

4 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

4 months ago - By: Yahoo Finance - Mentions: GILD MSFT SNY

Kymera weakness a buying opportunity, says Stifel

4 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Proposed Public Offering

4 months ago - By: Stocktwits - Mentions: GILD VTI UBS TSLA

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit

4 months ago - By: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

4 months ago - By: Gilead Sciences, Inc. - Mentions: GILD

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

5 months ago - By: Yahoo Finance - Mentions: CPRX SERV UBER APP

Needham Bank to acquire BankProv to expand market reach

5 months ago - By: Yahoo Finance - Mentions: CLF ITGR COMP HRL ...

Why Cleveland-Cliffs Stock Soared This Week

5 months ago - By: Yahoo Finance - Mentions: PVH SMMT COST DG ...

BofA Maintains Hold Rating on PVH Corp. (PVH), Sets $86 PT

5 months ago - By: Yahoo Finance - Mentions: MRUS KHC FIVE REGN ...

Why Merus N.V. (MRUS) Crashed On Wednesday

5 months ago - By: Yahoo Finance - Mentions: PINS JPM WFC RDDT ...

Reddit initiated, Pinterest upgraded: Wall Street's top analyst calls

5 months ago - By: Yahoo Finance - Mentions: CERO QDEL MCK ADAG ...

KYMERA THERAPEUTICS INC (KYMR) Stock News

KYMR Latest News, Press Relases and Analysis

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

Kymera Revenue Drops 55 Percent in Q2

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

Kymera weakness a buying opportunity, says Stifel

Kymera Therapeutics Announces Proposed Public Offering

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Needham Bank to acquire BankProv to expand market reach

Why Cleveland-Cliffs Stock Soared This Week

BofA Maintains Hold Rating on PVH Corp. (PVH), Sets $86 PT

Why Merus N.V. (MRUS) Crashed On Wednesday

Reddit initiated, Pinterest upgraded: Wall Street's top analyst calls

Cero announces two granted U.S. patents, European patent application allowance